Search

Author/Creator Oxnard, Geoffrey

1. ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. (20th January 2022)

Authors:
Zhang, Liangliang; Hamdani, Omar; Gjoerup, Ole; Cho-Phan, Cheryl; Snider, Jeremy; Castellanos, Emily; Nimeiri, Halla; Frampton, Garrett; Venstrom, Jeffrey M.; Oxnard, Geoffrey; Klempner, Samuel J.; Schrock, Alexa B.
Journal:
JCO precision oncology
Issue:
Volume 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Issue 3 (March 2020)

Authors:
Sequist, Lecia V; Han, Ji-Youn; Ahn, Myung-Ju; Cho, Byoung Chul; Yu, Helena; Kim, Sang-We; Yang, James Chih-Hsin; Lee, Jong Seok; Su, Wu-Chou; Kowalski, Dariusz; Orlov, Sergey; Cantarini, Mireille; Verheijen, Remy B; Mellemgaard, Anders; Ottesen, Lone; Frewer, Paul; Ou, Xiaoling; Oxnard, Geoffrey
Journal:
Lancet oncology
Issue:
Volume 21:Issue 3(2020)
Page Start:
373
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search